---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093936"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:52:00.944770+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CytomX Q2 2024 cash $137.2M; revenue $25.1M; CX-904 update expected by year-end

## Summary
- Cash, equivalents and investments $137.2M at June 30, 2024, down from $150.3M at March 31, 2024.
- Total revenue $25.1M in Q2 2024, up from $24.7M in Q2 2023; R&D expense $25.2M incl. $5M milestone to AbbVie.
- CX-904 (EGFRxCD3) Phase 1a enrollment continues in PDAC, NSCLC, HNSCC; program update expected by end of 2024.
- CX-2051 (EpCAM ADC) Phase 1 dose escalation in third cohort; initial data expected in first half of 2025.
- CX-801 (IFNα2b cytokine) first clinical site active; initial data expected in 2025; $10M Astellas milestones achieved YTD.

## SEC filing metadata
- accession: 0000950170-24-093936
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000095017024093936/0000950170-24-093936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000095017024093936/ctmx-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093936
- JSON: https://secwatch.observer/filing/0000950170-24-093936.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093936.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.